I had not see this eye popping BIEI link before la
Post# of 1691
Posted On: 11/26/2015 11:51:19 AM
I had not see this eye popping BIEI link before last night during my many hour dd marathon. This link at the bottom of this post is a MUST read folks from top to bottom! "History and Partner Product Strategy." Studying the time table and other information charts in the bottom half of the link pages that include the following among other important topics:
.Priorities and Ramp Up
.Business Plan Strategy
.Product Launch and Revenue Projections
.Market Expansion
IN MY VERY STRONG OPINION, if the share structure stays around the current 60-100 mil o/s level, we are looking at a stock that will go into the $s very soon (up to $5-$10+ in 2016) and high $s ($20-$30+) within 1-2 years. Same for a buyout or partnership by a big pharma which the CEO has already suggested may happen in a fairly recent PR. We have all seen the PRs showing HUGE revenue projections in South American to $400 mil by 2020 and the BIEI patented Feldetrex Fibromyalgia drug where I read a projection of $1.8 bil annual revenues with competition for this particular drug in the U.S. only as follows:
Market & Competition:
• Lyrica ® by Pfizer
– $4.7B annual sales in U.S.
– Patent expires in 2016
• Cymbalta® by Eli Lilly
– U.S. Patent expired end of 2013
– $3.9 B annual U.S. sales in 2013
• Savella® by Actavis (Forrest Labs)
And, we can't overlook the multi-billion revenue potential of the patented Sequential Dialysis machine.
Sequential-Dialysis Technique is a methodology for the removal of molecules which are
harmful and responsible for causing diseases.
– Extracorporeal (outside the body) process to prevent the severe side effects
which are normally encountered with other treatments
– The methodology can be used for:
• The treatment of cancer and prevention of metastasis
• Reducing the effects of Traumatic Brain Injuries
• Eliminating the neuropathological changes created by Alzheimer's Disease.
• Preventing the death of anterior motor neurons in ALS
• Eradicating the causations of Infectious Diseases ,e.g., Ebola
The methodology involved in this technique is largely unexplored and has the
opportunity to create a huge market share within a $2 trillion industry.
All of this Awesome link information which includes 2015 market expansion into Brazil, South America, Central America, Asia, Europe, North America! And, the link page 28 says a PBI Holding Company is being set up in Brazil! I wonder if we will get shares of that as it indicates a shell is being obtained + we have seen the link. Is that for the JV or something else?? And the all important partnerships with the U.S. Department of Defense and the University of Texas Medical Center in El Paso, TX. BIEI will be a LONG HOLD FOR ME! Institutions/Funds are on the way IMO to help take the stock up to major levels. The VALUABLE BIEI 2015 link as follows:
http://www.premierbiomedical.com/wp-content/u...Sep-15.pdf
.Priorities and Ramp Up
.Business Plan Strategy
.Product Launch and Revenue Projections
.Market Expansion
IN MY VERY STRONG OPINION, if the share structure stays around the current 60-100 mil o/s level, we are looking at a stock that will go into the $s very soon (up to $5-$10+ in 2016) and high $s ($20-$30+) within 1-2 years. Same for a buyout or partnership by a big pharma which the CEO has already suggested may happen in a fairly recent PR. We have all seen the PRs showing HUGE revenue projections in South American to $400 mil by 2020 and the BIEI patented Feldetrex Fibromyalgia drug where I read a projection of $1.8 bil annual revenues with competition for this particular drug in the U.S. only as follows:
Market & Competition:
• Lyrica ® by Pfizer
– $4.7B annual sales in U.S.
– Patent expires in 2016
• Cymbalta® by Eli Lilly
– U.S. Patent expired end of 2013
– $3.9 B annual U.S. sales in 2013
• Savella® by Actavis (Forrest Labs)
And, we can't overlook the multi-billion revenue potential of the patented Sequential Dialysis machine.
Sequential-Dialysis Technique is a methodology for the removal of molecules which are
harmful and responsible for causing diseases.
– Extracorporeal (outside the body) process to prevent the severe side effects
which are normally encountered with other treatments
– The methodology can be used for:
• The treatment of cancer and prevention of metastasis
• Reducing the effects of Traumatic Brain Injuries
• Eliminating the neuropathological changes created by Alzheimer's Disease.
• Preventing the death of anterior motor neurons in ALS
• Eradicating the causations of Infectious Diseases ,e.g., Ebola
The methodology involved in this technique is largely unexplored and has the
opportunity to create a huge market share within a $2 trillion industry.
All of this Awesome link information which includes 2015 market expansion into Brazil, South America, Central America, Asia, Europe, North America! And, the link page 28 says a PBI Holding Company is being set up in Brazil! I wonder if we will get shares of that as it indicates a shell is being obtained + we have seen the link. Is that for the JV or something else?? And the all important partnerships with the U.S. Department of Defense and the University of Texas Medical Center in El Paso, TX. BIEI will be a LONG HOLD FOR ME! Institutions/Funds are on the way IMO to help take the stock up to major levels. The VALUABLE BIEI 2015 link as follows:
http://www.premierbiomedical.com/wp-content/u...Sep-15.pdf
(0)
(0)